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SUMMARY Although the outcomes of various treatment modalities 
for vitiligo have been studied extensively, the influence of the partici-
pant’s characteristics on treatment response has not been thoroughly 
investigated. Therefore, we retrospectively investigated treatment ef-
fects and their association with clinical characteristics in Japanese pa-
tients with vitiligo. The charts of patients with vitiligo treated in our in-
stitution were reviewed. Clinical response was evaluated as a marked 
response rate, defined as  repigmentation in >75% of the initial lesion-
al area. 162 patients were treated with phototherapy, while 69 were 
treated with topical mono-therapy. The patients treated with photo-
therapy and those treated with both phototherapy and topical treat-
ment demonstrated significantly higher clinical response rates com-
pared to patients treated solely with topical mono-therapy (marked 
response rate: 19.1% vs. 5.8%, P<0.05; and 23.5% vs. 5.8%, P<0.01, re-
spectively). Among the phototherapy-treated patients, younger sub-
jects (≤15 years old) were more responsive to phototherapy compared 
to older patients (37.0% vs. 15.6%; P=0.015). The disease subtypes did 
not affect treatment response. In conclusion, phototherapy appears 
to have a therapeutic effect superior to topical mono-therapy on both 
focal and generalized vitiligo, especially in younger patients. Thus, any 
type of psychosocially devastating lesions in a pediatric patient may 
be a good target for phototherapy.
KeY woRdS: excimer laser, focal vitiligo, generalized vitiligo, narrow-
band UVB, pediatric.
IntRodUCtIon
Vitiligo is a common, acquired, depigmenting 
disease caused by selective destruction of cutane-
ous melanocytes. This disfiguring disease affects 
both sexes equally and can be developed at any age. 
The reported prevalence of vitiligo is 0.5% to 1%, 
and this disorder significantly impairs the patients’ 
quality of life (1). While genetic, autoimmune, neu-
ronal, biochemical, oxidative stress-induced, and 
viral mechanisms have been proposed, the precise 
etiology remains to be determined. There are vari-
ous treatment options for vitiligo that include pho-
totherapy (psoralen and ultraviolet A (PUVA), narrow 
band ultraviolet B (NBUVB), and 308-nm excimer 
laser), topical therapy (topical corticosteroids, topi-
cal vitamin D3 analogues, and topical calcineurin in-
hibitors), and surgical therapy (suction blister grafts, 
split thickness grafts, and minigrafts). Several review 
articles concluded that topical corticosteroids are the 
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intervention of choice for localized vitiligo, and that 
phototherapy is the intervention of choice for gener-
alized vitiligo (2,3). However, since previous studies 
had varied designs and outcome measurements, no 
definitive treatment strategy has been established to 
date (4). In addition, variations in participants’ charac-
teristics, including skin color, age or duration of the 
disease, and extent and type of vitiligo may cause the 
response to treatment to vary (4). Thus, it is impor-
tant to accumulate enough evidence to create a stan-
dardized treatment protocol. With this in mind, we 
conducted a retrospective study of vitiligo patients 
in our institution in order to evaluate the response to 
various types of treatments and their association with 
the clinical characteristics of the patients.
MethodS
The study included patients with vitiligo who vis-
ited the Department of Dermatology at the Juntendo 
University Hospital from 2006 to 2011. We obtained 
written, informed consent from each patient as well 
as approval from the institutional review board. The 
patients’ characteristics (age, age of onset, duration, 
sex, family history, comorbidities, disease localiza-
tion, disease subtypes (1), and the presence of halo 
nevi and the Kobner phenomenon) and the treat-
ment course were recorded. Laboratory results, in-
cluding thyroid function tests (thyroid stimulating 
hormone, free T4, anti-thyroglobulin antibodies, and 
anti-thyroid peroxidase antibodies) and the presence 
of other autoantibodies, were also assessed.
When phototherapy was used, the modalities, 
treatment duration, frequency, initial dose, total 
amount of irradiation, adverse events (AEs), and 
concomitant use of topical therapy (corticosteroids, 
calcineurin inhibitors, and vitamin D3 analogues) 
were noted. The mean initial doses were 0.28 J/cm2 
for PUVA, 0.24 J/cm2 for NBUVB, and 0.14 J/cm2 for 
excimer laser. The optimal maintenance dose was 
set below the minimal erythema dose. Topical me-
thoxypsoralen was applied prior to PUVA exposure. 
Liver and renal function tests were also performed 
before PUVA was started. Over 6-months of topical 
treatment, either as the sole treatment or along with 
phototherapy, were taken into account. Due to the 
potential risk of carcinogenesis, topical calcineurin 
inhibitors were not used with phototherapy.
Clinical outcomes were evaluated using the fol-
lowing repigmentation grading: no response, mild 
response (<25% repigmentation), moderate re-
sponse (25% to 50% repigmentation), good response 
(50% to 75% repigmentation), and marked response 
(>75% repigmentation) (5). Statistical analyses were 
performed using the Mann–Whitney U-test for two-
group comparisons and Fisher’s exact probability test 
for the analysis of frequencies. Bonferroni correction 
was used in multiple comparisons. Statistical signifi-
cance was defined as a P value of <0.05.
ReSUltS
Patient characteristics are summarized in Table 1. 
We analyzed the data of 121 men and 110 women. 
The most common lesional site was the face (56.7%), 
followed by the chest and abdomen (35.6%), hands 
(26.6%), and the neck (25.8%). Vitiligo vulgaris was 
the most common subtype (42.9%). Topical vitamin 
D3 derivatives were used for 48.9% of the patients, as 
well as topical corticosteroids (39.1%) and topical cal-
Value
Characteristc n = 231
Age (years) 38.2 ± 23.0
Age at onset (years) 33.1 ± 23.0
Duration (years) 4.9 ± 9.0
Sex (male/female) 121/110
Halo nevi (%) 2.1
Family history of vitiligo (%) 3.4
ANA titer >160 (%) 2.6
Abnormal TFTs (%) 10.3
Subtypes (%)
  Acrofacial 7.7
  Focal 29.6
  Segmental 18.9
  Universal 0.9
  Vulgaris 42.9
Localization (%)
  Head 14.2
  Face 56.7
  Neck 25.8
  Chest/abdomen 35.6
  Back 15.5
  Upper extremities 18.9
  Lower extremities 15.0
  Groin 19.3
  Hands 26.6
  Feet 7.7
Comorbidities (%)
  Hypothyroidism 3.0
  Hyperthyroidism 0.4
  Alopecia areata 4.3
  Atopic dermatitis 6.1
ANA = Anti-nuclear antibody; TFTs = thyroid function tests.
table 1. Subject characteristics
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cineurin inhibitors (7.3%). A small percentage of the 
patients (2.1%) underwent suction blister grafts as a 
surgical procedure. Atopic dermatitis was the most 
common comorbidity (6.8% men and 5.8% women) 
followed by alopecia areata (3.4% men and 5.8% 
women), asthma (3.4% men and 3.9% women), and 
hypothyroidism (0.9% men and 5.8% women).
Out of all patients, 162 were treated with photo-
therapy, and the remaining 69 patients were treated 
with topical mono-therapy. The efficacy of photo-
therapy was clearly superior to that of topical mono-
therapy, with marked response rates of 19.1% and 
5.8%, respectively (P < 0.05, Table 2). There were no 
differences in therapeutic response to phototherapy 
based on disease subtypes. Marked response rates 
were 21.4% (acrofacial), 22% (focal), 16% (segmental), 
and 18.3% (vulgaris). Among the 162 patients who 
received phototherapy, 14, 39, and 109 were treated 
with PUVA, NBUVB, and excimer laser, respectively. 
The mean number of irradiations in each modality 
was 21.6, 34.5, and 39.3, respectively. Of those treat-
ed with PUVA, 42.9% showed marked improvement, 
whereas 12.8% of those treated with NBUVB and 
18.3% of those treated with excimer laser showed 
marked responses (Table 2). Thus, the marked re-
sponse rate to PUVA (42.9%) was significantly higher 
compared with non-PUVA phototherapy (15.9%; P = 
0.023).
Concomitant use of topical medicine with photo-
therapy has been reported to improve the therapeu-
tic outcome in some cases (6,7). Therefore, we also in-
vestigated whether administering topical therapy in 
addition to phototherapy improved therapeutic out-
comes in this study population. Among the 162 pa-
tients treated with phototherapy, 81 were also treated 
with topical therapy, whereas the remaining 81 were 
treated with mono-phototherapy. Concomitant use 
of phototherapy and topical ointment demonstrated 
significantly higher treatment efficacy compared to 
topical mono-therapy, and tended to show better ef-
ficacy than mono-phototherapy (marked response: 
23.5% vs. 5.8%, P = 0.0029; 23.5% vs. 14.8%; P = 0.17; 
Table 2).
A previous study reported that vitiligo patients 
under 15 years of age were more susceptible to pho-
totherapy (5). Thus, we performed a separate analysis 
of this population. As expected, patients ≤15 years 
of age (n = 26) were more responsive to photother-
apy compared with patients >15 years old (n = 136; 
marked response: 37.0% vs. 15.6%; P = 0.015). There 
were no significant differences in disease duration, 
sex, or disease subtypes between the two age groups 
(Table 3).
Adverse reactions to either therapy were mild, 
and no patients discontinued the treatment. In pa-










Phototherapy 162 31 (19.1%)* 56 (34.6%) 23 (14.2%) 43 (26.5%) 9 (5.6%)
Phototherapy with topical 
therapy 81 19 (23.5%)† 25 (30.9%) 14 (17.3%) 19 (23.5%) 4 (4.9%)
Mono-phototherapy 81 12 (14.8%) 31 (38.3%) 9 (11.1%) 24 (29.6%) 5 (6.2%)
Topical mono-therapy 69 4 (5.8%)*† 37 (53.6%) 3 (4.3%) 18 (26.1%) 7 (10.1%)
Subtypes of phototherapy-
treated patients
Acrofacial 14 3 (21.4%) 6 (42.9%) 0 (0%) 4 (28.6%) 1 (7.1%)
Focal 50 11 (22.0%) 24 (48.0%) 1 (2.0%) 12 (24.0%) 2 (4.0%)
Segmental 25 4 (16.0%) 11 (44.0%) 0 (0%) 10 (40.0%) 0 (0%)
Universal 2 0 (0%) 0 (0%) 1 (50.0%) 1 (50.0%) 0 (0%)
Vulgaris 71 13 (18.3%) 15 (21.1%) 21 (29.6%) 16 (22.5%) 6 (8.5%)
PUVA 14 6 (42.9%) 4 (28.6%) 1 (8.3%) 2 (14.3%) 1 (7.1%)
NBUVB 39 5 (12.8%) 12 (30.8%) 8 (20.5%) 11 (28.2%) 3 (7.7%)
Excimer 109 20 (18.3%) 40 (36.7%) 14 (12.8%) 30 (27.5%) 5 (4.6%)
PUVA = Proralen and ultraviolet A; NBUVB = Narrow band ultraviolet B
table 2. Clinical efficacy of different treatment options in vitiligo
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(12.3%) of mild burns and 14 cases (8.6%) of skin ir-
ritation. In topically treated patients, four cases of 
telangiectasia, two cases of skin irritation, one case 
of hypertrichosis, and one case of skin atrophy were 
also observed.
dISCUSSIon
Currently, no optimal therapeutic strategy for the 
treatment of vitiligo has been defined. Phototherapy 
markedly improves the clinical picture in many cases, 
but a cure has not been achieved. In addition, the 
therapeutic effect varies among patients, and the 
treated patients often fail to maintain their initial re-
sponse to phototherapy (8). However, considering 
the psychologically devastating nature of the disease, 
improvement in treatment outcomes is highly desir-
able.
As expected, phototherapy, especially the combi-
nation of phototherapy and topical therapy, was sig-
nificantly more effective than topical mono-therapy. 
Importantly, in the group treated with phototherapy, 
patients under 15 years of age were significantly 
more responsive to treatment. Although there is no 
consensus on the superior efficacy of phototherapy 
in younger patients, there are two previous studies 
that also support our finding. In an observational, 
prospective study, Percivalle et al. (5) demonstrated 
that 14.3% of 28 patients between 3 and 15 years 
of age achieved repigmentation of ≥75%. This re-
sult was better than that of their previous study in 
an adult population, which showed that 3.8% of 53 
adult patients achieved repigmentation of ≥75% (9). 
Furthermore, Brazzelli et al. (10) showed in a prospec-
tive study of 60 cases that patients under 20 years 
achieved a higher repigmentation rate in lesions of 
the neck and the extremities than patients >20 years 
old. Although the mechanism underlying improved 
outcomes in younger patients has not been eluci-
dated, it may be partly attributed to the aging of re-
sidual melanocytes in the lesional skin. While vitiligo 
is caused by a selective destruction of melanocytes, 
these cells are unlikely to be completely lost even in 
the lesional skin of vitiligo (11). The density of mela-
nocytes is reported to decrease progressively during 
adulthood by approximately 10% per decade (12). Al-
though both PUVA and NBUVB promote melanocyte 
migration and proliferation, and create a favorable 
environment for melanocyte growth (13,14), aging 
may diminish these effects on residual melanocytes 
in the lesional skin. Taken together, phototherapy ap-
pears to be a good treatment option, especially for 
pediatric vitiligo patients.
In our study, phototherapy was considered as a 
treatment of choice only in adult and pediatric pa-
tients who could not be adequately managed with 
topical treatment. Since previous studies have demon-
strated the effectiveness and safety of phototherapy, 
including NBUVB and excimer laser, both in pediatric 
patients and adults (15,17), we used these treatments 
for pediatric patients with vitiligo, while carefully 
observing adverse reactions. A recent guideline also 
suggests phototherapy as a treatment of choice when 
more conservative treatment is ineffective (18). In our 
study, the safety assessment revealed mild burns in 
12.3% and skin irritation in 8.6% of the phototherapy-
treated patients, all of which resolved spontaneously. 
So far, skin cancer did not emerge in neither adults nor 
children treated with phototherapy in our institution. 
However, unlike NBUVB (19), PUVA carries a slightly 
increased risk of both non-melanoma skin cancer and 
melanoma (20-22). Premature photoaging of the skin 
is also a concern with prolonged use of phototherapy 
(23). Therefore, it is necessary to provide patients with 
an extensive explanation of these possible long-term 
adverse effects, and obtain written informed consent 
before the use of phototherapy. Long-term follow-up 
is also necessary, especially for children.
With regard to the modalities of phototherapy, 
many previous studies have shown that NBUVB has 
equivalent or higher rates of repigmentation com-
pared to PUVA (63% vs. 51%), although PUVA may 
yield a quicker response (3). According to Hong et al. 
≤15 years old >15 years old
n = 26 n = 136
Duration (years) 1.4 ± 1.5 5.6 ± 12.0
Sex (male/female ratio) 0.9 1.7
Subtypes (%)
  Acrofacial 0 10.4
  Focal 0 1.5
  Segmental 42.3 27.6
  Universal 64.6 12.7
  Vulgaris 26.9 47.8
Treatment response (%)
  Marked response 37.0* 15.6*
  Good response 44.4 32.6
  Moderate response 0 17.0
  Mild response 18.5 28.1
  No response 0 6.7
*P < 0.05
table 3. Comparison of pediatric and adult pa-
tients with vitiligo treated with phototherapy
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(24), excimer laser has a better clinical outcome than 
NBUVB. In contrast, the clinical efficacy of PUVA was 
superior to that of both NBUVB and excimer laser 
in our study. However, the number of the patients 
treated with PUVA was relatively small compared 
with those treated with NBUVB or excimer laser, be-
cause the latter two modalities are now the most fre-
quently used in our institution. The small number of 
PUVA-treated patients may be partly responsible for 
the difference in treatment efficacy between the two 
studies. However, PUVA may be more effective for a 
certain population of patients with vitiligo, and thus 
further investigation is needed.
Our results showed that the clinical subtypes of 
vitiligo did not affect the response to phototherapy. 
Although several previous studies reported that seg-
mental vitiligo is less likely to respond to photothera-
py, this finding is not always consistent with other ob-
servations (25). As excimer laser can only be applied 
to a limited, small, depigmented lesion, phototherapy 
should be considered for both focal and generalized 
depigmentation.
ConClUSIon
Our retrospective study suggests that photothera-
py has a positive therapeutic effect on both focal and 
generalized vitiligo, especially in younger patients. 
Therefore, even a small, limited, depigmented lesion 
in a pediatric patient can be a good target for photo-
therapy if the symptom is psychosocially devastating. 
Since our study has some limitations due to its ret-
rospective nature and the small number of patients, 
further accumulation of evidence is recommended.
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